Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1003833

registered interest
date	09/11/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure the (a) supply and (b) availability of the drug Methotrexate after the UK leaves the EU.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	189738
answer	answer is ministerial correction date of answer 15/11/2018 answer text <p>The United Kingdom’s position on medicines regulation remains clear. We are working to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 15/11/2018 12:46:13 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

894862

registered interest
date	30/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Seafood
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to promote the health benefits of eating more fish and incorporating the principles of the Seafood 2040 Strategy into the NHS, care homes, nursing homes and home care.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	139534
answer	answer is ministerial correction date of answer 03/05/2018 answer text <p>The Government recommends eating at least two portions of fish a week, including a portion of oily fish. This recommendation is promoted through a variety of communications including the national healthy eating model the Eatwell Guide, Public Health England’s (PHE’s) catering guidance (including for older adults in residential care), and the NHS Choices website.</p><p> </p><p>PHE, together with representatives from the Department, the National Health Service, the Seafish Industry Authority and others, are part of the ‘Plan for the Public Procurement of Food Implementation Taskforce’ that has been established by the Department for Environment, Food and Rural Affairs. Encouraging and promoting consumption of fish is a component of this plan through implementation of the Government Buying Standards for Food and Catering Services.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 03/05/2018 13:16:19 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

886240

registered interest
date	18/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to promote timely and accurate diagnosis of inflammatory bowel disease.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	136435
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>NHS England and clinical commissioning groups (CCGs) are responsible for commissioning services for people with inflammatory bowel disease (IBD).</p><p> </p><p>To support local commissioning, the National Institute for Health and Care Excellence (NICE) has published best practice guidance for the timely and accurate diagnosis, treatment care and support for patients with IBD.</p><p> </p><p>NICE has published the guidance ’Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’ which recommends that that faecal calprotectin testing as an option to help support clinicians distinguish between IBD and irritable bowel syndrome.</p><p> </p><p>Faecal calprotectin testing will therefore help decide who should be referred for colonoscopy (the Gold Standard diagnostic test) and who may be amenable to management in primary care. Primary and secondary care clinicians are expected to follow the good practice guidelines and the quality standard.</p><p> </p><p>NHS England commissions specialised Intestinal Failure Services. A number of these centres are currently involved in multidisciplinary training of health professionals in specialised IBD care. In addition, the Association of Coloproctology of Great Britain and Ireland are currently in the process of setting out national standards for surgical management of IBD. Patients are managed by a multidisciplinary team (MDT) with the necessary expertise to enable appropriate monitoring, support and advice necessary to manage the side effects of treatment, flare-ups and to review and maintain remission. MDT support and the associated diagnostic and investigative resource necessary for IBD patient care will usually be found in secondary care settings.</p><p> </p><p>General practitioners and clinicians are expected to take account of relevant NICE guidance to ensure that patients with suspected inflammatory bowel disease are referred quickly and efficiently, and have a specialist assessment within four weeks of referral.</p><p> </p><p>The NICE guidelines are available at the following links:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085" target="_blank">www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085</a></p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725" target="_blank">www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 136439 136442 136444 question first answered 23/04/2018 15:18:40 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

886244

registered interest
date	18/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease: Diagnosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to increase (a) access to and (b) use of faecal calprotectin in primary care in cases where inflammatory bowel disease is suspected.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	136439
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>NHS England and clinical commissioning groups (CCGs) are responsible for commissioning services for people with inflammatory bowel disease (IBD).</p><p> </p><p>To support local commissioning, the National Institute for Health and Care Excellence (NICE) has published best practice guidance for the timely and accurate diagnosis, treatment care and support for patients with IBD.</p><p> </p><p>NICE has published the guidance ’Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’ which recommends that that faecal calprotectin testing as an option to help support clinicians distinguish between IBD and irritable bowel syndrome.</p><p> </p><p>Faecal calprotectin testing will therefore help decide who should be referred for colonoscopy (the Gold Standard diagnostic test) and who may be amenable to management in primary care. Primary and secondary care clinicians are expected to follow the good practice guidelines and the quality standard.</p><p> </p><p>NHS England commissions specialised Intestinal Failure Services. A number of these centres are currently involved in multidisciplinary training of health professionals in specialised IBD care. In addition, the Association of Coloproctology of Great Britain and Ireland are currently in the process of setting out national standards for surgical management of IBD. Patients are managed by a multidisciplinary team (MDT) with the necessary expertise to enable appropriate monitoring, support and advice necessary to manage the side effects of treatment, flare-ups and to review and maintain remission. MDT support and the associated diagnostic and investigative resource necessary for IBD patient care will usually be found in secondary care settings.</p><p> </p><p>General practitioners and clinicians are expected to take account of relevant NICE guidance to ensure that patients with suspected inflammatory bowel disease are referred quickly and efficiently, and have a specialist assessment within four weeks of referral.</p><p> </p><p>The NICE guidelines are available at the following links:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085" target="_blank">www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085</a></p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725" target="_blank">www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 136435 136442 136444 question first answered 23/04/2018 15:18:40 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

886247

registered interest
date	18/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps (a) his Department and (b) NHS England are taking to improve the training for healthcare professionals in primary care to (i) diagnose and (ii) manage inflammatory bowel disease.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	136442
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>NHS England and clinical commissioning groups (CCGs) are responsible for commissioning services for people with inflammatory bowel disease (IBD).</p><p> </p><p>To support local commissioning, the National Institute for Health and Care Excellence (NICE) has published best practice guidance for the timely and accurate diagnosis, treatment care and support for patients with IBD.</p><p> </p><p>NICE has published the guidance ’Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’ which recommends that that faecal calprotectin testing as an option to help support clinicians distinguish between IBD and irritable bowel syndrome.</p><p> </p><p>Faecal calprotectin testing will therefore help decide who should be referred for colonoscopy (the Gold Standard diagnostic test) and who may be amenable to management in primary care. Primary and secondary care clinicians are expected to follow the good practice guidelines and the quality standard.</p><p> </p><p>NHS England commissions specialised Intestinal Failure Services. A number of these centres are currently involved in multidisciplinary training of health professionals in specialised IBD care. In addition, the Association of Coloproctology of Great Britain and Ireland are currently in the process of setting out national standards for surgical management of IBD. Patients are managed by a multidisciplinary team (MDT) with the necessary expertise to enable appropriate monitoring, support and advice necessary to manage the side effects of treatment, flare-ups and to review and maintain remission. MDT support and the associated diagnostic and investigative resource necessary for IBD patient care will usually be found in secondary care settings.</p><p> </p><p>General practitioners and clinicians are expected to take account of relevant NICE guidance to ensure that patients with suspected inflammatory bowel disease are referred quickly and efficiently, and have a specialist assessment within four weeks of referral.</p><p> </p><p>The NICE guidelines are available at the following links:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085" target="_blank">www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085</a></p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725" target="_blank">www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 136435 136439 136444 question first answered 23/04/2018 15:18:40 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

886249

registered interest
date	18/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the NICE Quality Standard on inflammatory bowel disease, what steps he is taking to ensure that patients with suspected inflammatory bowel disease receive a specialist assessment within four weeks of referral.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	136444
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>NHS England and clinical commissioning groups (CCGs) are responsible for commissioning services for people with inflammatory bowel disease (IBD).</p><p> </p><p>To support local commissioning, the National Institute for Health and Care Excellence (NICE) has published best practice guidance for the timely and accurate diagnosis, treatment care and support for patients with IBD.</p><p> </p><p>NICE has published the guidance ’Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’ which recommends that that faecal calprotectin testing as an option to help support clinicians distinguish between IBD and irritable bowel syndrome.</p><p> </p><p>Faecal calprotectin testing will therefore help decide who should be referred for colonoscopy (the Gold Standard diagnostic test) and who may be amenable to management in primary care. Primary and secondary care clinicians are expected to follow the good practice guidelines and the quality standard.</p><p> </p><p>NHS England commissions specialised Intestinal Failure Services. A number of these centres are currently involved in multidisciplinary training of health professionals in specialised IBD care. In addition, the Association of Coloproctology of Great Britain and Ireland are currently in the process of setting out national standards for surgical management of IBD. Patients are managed by a multidisciplinary team (MDT) with the necessary expertise to enable appropriate monitoring, support and advice necessary to manage the side effects of treatment, flare-ups and to review and maintain remission. MDT support and the associated diagnostic and investigative resource necessary for IBD patient care will usually be found in secondary care settings.</p><p> </p><p>General practitioners and clinicians are expected to take account of relevant NICE guidance to ensure that patients with suspected inflammatory bowel disease are referred quickly and efficiently, and have a specialist assessment within four weeks of referral.</p><p> </p><p>The NICE guidelines are available at the following links:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085" target="_blank">www.nice.org.uk/guidance/cg152/resources/crohns-disease-management-pdf-35109627942085</a></p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725" target="_blank">www.nice.org.uk/guidance/cg166/resources/ulcerative-colitis-management-pdf-35109695126725</a></p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 136435 136439 136442 question first answered 23/04/2018 15:18:40 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

869377

registered interest
date	22/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 March to Question 132917, on Inflammatory Bowel Disease, if his Department will take further steps to ensure that every GP is made aware of the toolkit.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	133891
answer	answer is ministerial correction date of answer 27/03/2018 answer text <p>It is not the role of the Department to directly promote clinical toolkits to clinicians. As set out in the previous answer, the developers of the toolkit, Crohn’s and Colitis UK with the Royal College of General Practitioners, have undertaken a range of activities to promote general practitioners’ awareness of the new resource following its launch last summer.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 27/03/2018 16:18:17 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

864434

registered interest
date	15/03/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Inflammatory Bowel Disease
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that GPs receive a copy of Crohn's & Colitis UK's latest Inflammatory Bowel Disease toolkit to improve (a) awareness, (b) early diagnosis and (b) treatment plans for that condition.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	132917
answer	answer is ministerial correction date of answer 20/03/2018 answer text <p>In August 2017, Crohn’s and Colitis UK in partnership with the Royal College of General Practitioners (RCGP) launched a new Inflammatory Bowel Disease (IBD) toolkit: an online resource for general practitioners (GPs) and healthcare professionals designed to improve understanding of Crohn’s Disease and Ulcerative Colitis, collectively known as IBD. The Toolkit was developed as part of a 12 month project on IBD, and includes a range of resources for GPs to improve detection of inflammatory bowel disease and to support primary care clinicians in treating, managing and referring patients with the condition.</p><p> </p><p>The Toolkit was promoted at events across the United Kingdom and an IBD Twitter chat with an expert panel was held in February 2018. The Toolkit, regional events and Twitter session were all promoted to GPs via the RCGP website and newsletter and more widely by Crohn’s and Colitis UK. The Toolkit can be found at the following link:</p><p> </p><p><a href="http://www.rcgp.org.uk/clinical-and-research/resources/toolkits/inflammatory-bowel-disease-toolkit.aspx" target="_blank">www.rcgp.org.uk/clinical-and-research/resources/toolkits/inflammatory-bowel-disease-toolkit.aspx</a></p><p> </p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/03/2018 16:31:16 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

802550

registered interest
date	07/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Inflammatory Bowel Disease: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to increase the proportion of patients with inflammatory bowel disease who receive support and information in primary care and acute care to enable them to self-manage.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	118100
answer	answer is ministerial correction date of answer 12/12/2017 answer text <p>Inflammatory bowel disease (IBD) is the collective name used to describe ulcerative colitis and Crohn’s disease. To support commissioners to deliver local services for people with Crohn’s disease and ulcerative colitis, the National Institute for Health and Care Excellence (NICE) published, ‘Crohn’s Disease Management in Adults, Children and Young People’, updated in May 2016, and, ‘Ulcerative Colitis Management in Adults, Children and Young People’, in June 2013.</p><p> </p><p>The NICE Crohn’s clinical guideline makes clear that minimising psychological concerns and possible side effects of treatment are a key part of best practice for all people with Crohn's disease. The NICE Ulcerative Colitis clinical guideline highlights psychological support as being particularly important if a patient is considering surgery for their disease, and post-operatively, when surgery has taken place. Patient education, information and support are priorities in both guidelines. This can cover important information about diet and lifestyle, treatment and side-effects, as well signposting to support groups and other relevant services. Both guidelines can be found at the following links:</p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg152" target="_blank">www.nice.org.uk/guidance/cg152</a></p><p> </p><p><a href="http://www.nice.org.uk/guidance/cg166" target="_blank">www.nice.org.uk/guidance/cg166</a></p><p> </p><p>The IBD audit programme was established over 10 years ago with the aim of improving the quality and safety of care for people with IBD throughout the United Kingdom and during this time it has delivered important improvements against NICE standards. Audit reports have covered both treatment and patient experience, the latter of which captured information about quality of information and support at discharge, to help drive improvement in this area. In 2015, eight regional service improvement workshops were conducted by the IBD programme team to share expertise and examples of best practice, and to develop action plans to implement and evaluate improvement in IBD services. Attended by clinicians from across the country, a range of improvement initiatives were taken forward as a result, including around patient information and self-management. The report evaluating this important work and more information on the audit can be found at the following link:</p><p><a href="http://www.rcplondon.ac.uk/projects/ibd-programme" target="_blank">www.rcplondon.ac.uk/projects/ibd-programme</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 12/12/2017 14:00:51 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn

801021

registered interest
date	05/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Novartis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of the potential effect of the relocation of the European Medicines Agency on the future of the Novartis pharmaceutical (a) site and (b) production at that site.
tabling member constituency	Great Grimsby
tabling member printed	Melanie Onn
uin	117580
answer	answer is ministerial correction date of answer 11/12/2017 answer text <p>The Government is committed to ensuring a positive outcome for the whole life science sector that enhances competitiveness and builds on the success that we are rightly proud of, as we exit the European Union. Officials across government have been carrying out a programme of sectoral and regulatory analysis to identify the key factors for the life sciences sector that will affect our negotiations with the EU. Ultimately it is for the European Medicines Agency to comment on how it intends to operate from its new location, and what individual companies like Novartis might have to do differently.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/12/2017 17:40:39 answering member 4067 label Biography information for Steve Brine
tabling member	4464 label Biography information for Melanie Onn